Issue Type: Balancing Innovation, Value, and Drug Prices
does this show up on site? or is this internal?
in challenge narrative
-
Ethics of Clinical Trials to Evaluate Biosimilars
-
Bottom-Up Pricing Estimate for P-quad
-
Modeling P-quad
-
Balancing Innovation and Drug Pricing
-
Who Is Sowing Seeds of Confusion About The QALY?
-
Before Spending Billions, U.S. Hospitals Need to Study Remdesivir Further
-
Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead
-
Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
-
Time to Throw in the Towel on Biosimilars
-
Dr. Bach Testifies at U.S. Senate Committee on Finance’s First Hearing of Session